News & Updates
Filter by Specialty:
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
11 Dec 2023
One in six CYPs in SG develop long COVID
In Singapore, about one in six children and young persons (CYPs) developed long COVID, with persistence of ≥1 symptoms 3 months after an acute COVID-19 infection, a survey study suggests.
One in six CYPs in SG develop long COVID
11 Dec 2023
Empagliflozin of little benefit in patients hospitalized for COVID-19
In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.
Empagliflozin of little benefit in patients hospitalized for COVID-19
04 Dec 2023
Ensifentrine improves lung function, cuts exacerbations in COPD
The novel, selective, dual PDE*3 and PDE4 inhibitor ensifentrine improved lung function and reduced exacerbations in individuals with chronic obstructive pulmonary disease (COPD), findings from the ENHANCE**-1 and ENHANCE-2 trials have shown.
Ensifentrine improves lung function, cuts exacerbations in COPD
04 Dec 2023
Gastrointestinal issues linger long after COVID-19 recovery
Gut-brain interaction disorders and persistent gastrointestinal (GI) symptoms prevail 12–18 months following COVID-19 hospitalization, and these prolonged GI issues are associated with the severity of the symptoms during hospitalization and the psychological toll of the illness experience, according to a study.